WO2024106959A1 - Composition permettant de favoriser la régénération tissulaire comprenant des sphéroïdes de cellules souches - Google Patents

Composition permettant de favoriser la régénération tissulaire comprenant des sphéroïdes de cellules souches Download PDF

Info

Publication number
WO2024106959A1
WO2024106959A1 PCT/KR2023/018404 KR2023018404W WO2024106959A1 WO 2024106959 A1 WO2024106959 A1 WO 2024106959A1 KR 2023018404 W KR2023018404 W KR 2023018404W WO 2024106959 A1 WO2024106959 A1 WO 2024106959A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cell
cells
cell spheroids
spheroids
present
Prior art date
Application number
PCT/KR2023/018404
Other languages
English (en)
Korean (ko)
Inventor
권성근
최지숙
손영주
엄민례
정은지
Original Assignee
서울대학교병원
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교병원, 서울대학교 산학협력단 filed Critical 서울대학교병원
Priority claimed from KR1020230158492A external-priority patent/KR20240072071A/ko
Publication of WO2024106959A1 publication Critical patent/WO2024106959A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells

Definitions

  • the present invention relates to a composition for promoting tissue regeneration containing stem cell spheroids.
  • pluripotent stem cells which have the ability to form various organs through proliferation and differentiation, are recognized as capable of treating most diseases and fundamentally resolving organ damage. .
  • Stem cells are cells that can differentiate into various cells that make up biological tissues, and are a general term for undifferentiated cells in the pre-differentiation stage that can be obtained from each tissue of the embryo, fetus, and adult.
  • Stem cells differentiate into specific cells by differentiation stimulation (environment), have the characteristic of producing cells identical to themselves (self-renewal) through cell division, and can also differentiate into different cells depending on differentiation stimulation. It is characterized by its flexibility.
  • Stem cells can be divided into pluripotency, multipotency, totipotency, and unipotency stem cells according to their differentiation capacity.
  • Pluripotent stem cells are cells that have the potential to differentiate into all types of cells, and some stem cells have the potential to be multipotent or unipotent.
  • Stem cells have the ability to promote the growth and differentiation of surrounding cells through the expression of various bioactive factors (paracrine effect), and as a raw material for cell therapy, they have attracted much attention in the field of regenerative medicine, which is closely related to incurable and degenerative diseases and organ regeneration. I'm receiving it.
  • cell therapeutics are medicines manufactured by manipulating cells by physical, chemical, or biological methods, such as culturing or selecting cells in vitro.
  • Most cell therapeutics use single cells grown in vitro. It was developed in the form of a suspension suspended in additives.
  • single cells in suspension preparations do not regenerate directly due to physical and chemical stress in the transplantation environment and anoikis, which is cell-matrix and cell-cell non-adherence cell death (detachment-induced apoptosis).
  • anoikis which is cell-matrix and cell-cell non-adherence cell death (detachment-induced apoptosis).
  • it cannot form tissues and only indirect effects can be expected from substances secreted by cells.
  • a spheroid-type cell therapy that can increase the cell survival rate after transplantation into the body and enhance the therapeutic effects of cell therapy such as anti-inflammatory and vascular regeneration by reaggregating and recombining cells using 3D culture method. It is actively underway.
  • the technology for manufacturing cell spheroids is a common technology, and is especially widely used in the field of anticancer drug development. It is also used in the field of tissue regeneration/reconstruction due to the characteristic of three-dimensional cell culture.
  • tissue regeneration/reconstruction due to the characteristic of three-dimensional cell culture.
  • the present inventors attempted to manufacture standardized stem cell spheroids that can be manufactured in uniform sizes and utilize them in the development of cell therapeutics that can promote the regeneration of various tissues.
  • the present invention has been made to solve the problems of the prior art as described above, and the purpose of the present invention is to provide a composition or cell therapeutic agent for promoting tissue regeneration, comprising stem cell spheroids as an active ingredient.
  • the present invention provides a composition for promoting tissue regeneration, comprising stem cell spheroids as an active ingredient.
  • the stem cells include bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, embryonic stem cell-derived mesenchymal stem cells, tonsil-derived mesenchymal stem cells, and induced pluripotent stem cell-derived mesenchyme. It may be one or more selected from the group consisting of stem cells, but is not limited thereto.
  • the tissue may be one or more selected from the group consisting of skin, fat, salivary glands, trachea, airway, vocal cords, and muscle, but is not limited thereto.
  • the composition may further include a support for tissue engineering, but is not limited thereto.
  • the stem cell spheroid may have improved expression of bioactive factors related to promoting tissue regeneration, but is not limited thereto.
  • the bioactive factors include vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), and fibroblast growth factors (FGFs).
  • VEGF vascular endothelial growth factor
  • MMPs matrix metalloproteinases
  • FGFs fibroblast growth factors
  • EGF epidermal growth factor
  • HGF hepatocyte growth factor
  • PDGFs platelet-derived growth factors
  • PlGF placental growth factor
  • GM-CSF Granulocyte-macrophage colony-stimulating factor
  • TGF- ⁇ Transforming growth factor beta
  • Angiopoietin It may be more than this, but is not limited thereto.
  • the stem cells can promote new blood vessel formation, but are not limited thereto.
  • the stem cell spheroid may have a diameter of 100 to 500 ⁇ m, but is not limited thereto.
  • the present invention provides a cell therapeutic agent for promoting tissue regeneration, comprising stem cell spheroids as an active ingredient.
  • the present invention provides a method for promoting tissue regeneration, comprising administering a composition containing stem cell spheroids as an active ingredient to an individual in need thereof.
  • the present invention provides a use for promoting tissue regeneration of a composition containing stem cell spheroids as an active ingredient.
  • the present invention provides the use of a composition containing stem cell spheroids as an active ingredient for the production of an agent for promoting tissue regeneration.
  • Stem cell spheroids according to the present invention can be manufactured in uniform sizes and are standardized, and the tissue regeneration rate is faster than two-dimensional cultured stem cells, and the regenerated tissue has a high degree of similarity to the original tissue.
  • the stem cell spheroid according to the present invention has an excellent effect on the regeneration of various tissues such as salivary glands, trachea, vocal cords, muscles, skin, and fatty tissue through actions such as formation of new blood vessels, and is used as a cell therapy for various tissue diseases, etc. It is expected that it will be useful.
  • Figure 1 is a diagram showing the results of confirming the diameter of stem cell spheroids according to the number of stem cells according to one embodiment of the present invention.
  • Figure 2 is a diagram showing the results of analyzing the correlation between the diameter of a single cell, the diameter of a stem cell spheroid and the initial number of single cells according to an embodiment of the present invention using logistic regression analysis.
  • the blue dotted line in Figure 2 represents the regression line.
  • Figure 3 is a 3D graph showing the correlation between the diameter of a single cell, the diameter of a stem cell spheroid, and the initial number of single cells according to an embodiment of the present invention.
  • the left drawing of Figure 3 shows the stem cell spheroid diameter according to the diameter of the single cell and the number of single cells, where the black dot is a single cell with a diameter of 10.4 ⁇ m, the white dot is a single cell with a diameter of 14.0 ⁇ m, and the red dot is 15.2 ⁇ m.
  • a single cell in diameter, a green dot represents a single cell with a diameter of 21.9 ⁇ m, and a yellow dot represents a single cell with a diameter of 23.7 ⁇ m.
  • the drawing on the right of Figure 3 shows the diameter of a single cell (x) and the diameter of a spheroid (y) to predict the number of single cells (f) required for stem cell spheroid production, and the blue mesh represents Regression (3D, Gaussian).
  • Figure 4 is a diagram showing the results of applying the function for calculating the required number of single cells in various culture vessels according to an embodiment of the present invention.
  • Figure 5a is a diagram showing the results of observing the degree of hypoxia inside the spheroid according to the stem cell spheroid diameter according to an embodiment of the present invention using a fluorescence microscope.
  • Figure 5b is a diagram showing the results of confirming the cell survival rate according to the diameter of the stem cell spheroid according to one embodiment of the present invention.
  • Figure 5c is a diagram showing the results of confirming the cumulative secretion amount of bioactive factors according to the diameter of the stem cell spheroid according to one embodiment of the present invention using ELISA.
  • Figure 5d is a diagram showing the results of confirming the expression of various bioactive factors related to angiogenesis by treatment of stem cell spheroids according to one embodiment of the present invention (blue line: each bioactive factor secreted by two-dimensional cultured stem cells) Standard line where the amount of activator is normalized to 1).
  • Figure 6a is a diagram showing the results confirming the tube formation inducing efficacy of stem cell spheroids through co-culture of stem cell spheroids and GFP-HUVEC according to an embodiment of the present invention.
  • Figure 6b is a diagram quantifying the results of Figure 6a.
  • Figure 7a is a diagram showing the results of H&E staining of salivary gland tissue by stem cell spheroid injection after radiation irradiation according to one embodiment of the present invention.
  • Figure 7b is a diagram showing the results of confirming the mucin secretion function of the salivary glands by stem cell spheroid injection after radiation irradiation according to an embodiment of the present invention.
  • Figure 7c is a diagram showing the results of functional and morphological evaluation of salivary glands by stem cell spheroid injection after radiation irradiation according to an embodiment of the present invention.
  • Figure 8a is a view showing the attachment of two-dimensional cultured stem cells and stem cell spheroids applied to the inside and outside of an organ support according to one embodiment of the present invention.
  • Figure 8b shows the transplantation of an organ scaffold coated with two-dimensionally cultured stem cells and stem cell spheroids into an animal model with partial tracheal defect according to an embodiment of the present invention, and the appearance of the organ scaffold transplanted 14 weeks after transplantation. It is a drawing.
  • Figure 8c is a view showing an endoscopic image of the airway after transplantation of an organ scaffold coated with two-dimensionally cultured stem cells and stem cell spheroids according to an embodiment of the present invention.
  • Figure 8d is a diagram showing the results of evaluating the efficacy of reconstructing the shape of the airway mucosa after transplantation of an organ scaffold coated with two-dimensionally cultured stem cells and stem cell spheroids according to an embodiment of the present invention.
  • Figure 8e is a diagram showing the results of evaluating the efficacy of rebuilding airway mucosal function after transplantation of an organ scaffold coated with two-dimensionally cultured stem cells and stem cell spheroids according to an embodiment of the present invention.
  • Figure 8f shows the airway mucosal tissue regenerated inside the scaffold after transplantation of an organ scaffold coated with two-dimensionally cultured stem cells and stem cell spheroids according to an embodiment of the present invention (left view of Figure 8F) and the organ outside the scaffold.
  • This is a diagram showing the results of evaluating the neovascularization efficacy of the muscle layer covering (right diagram of Figure 8f).
  • Figure 9 is a diagram showing the results of confirming the effect of stem cell spheroids in rebuilding aging vocal cords according to an embodiment of the present invention.
  • Figure 10a is a view showing Matrigel encapsulated with stem cell spheroids covered over damaged blood vessels after producing an ischemic lower extremity disease animal model according to an embodiment of the present invention.
  • Figure 10b is a diagram showing the results of measuring the blood flow rate after inducing tissue regeneration through stem cell spheroid transplantation in an ischemic lower extremity disease animal model according to an embodiment of the present invention.
  • Figure 10c is a diagram showing the blood flow and appearance of the foot after inducing tissue regeneration through stem cell spheroid transplantation in an ischemic lower extremity disease animal model according to an embodiment of the present invention.
  • Figure 10d is a diagram showing the results of H&E staining of a cross section of the thigh muscle after inducing tissue regeneration through stem cell spheroid transplantation in an ischemic lower extremity disease animal model according to an embodiment of the present invention.
  • Figure 10e is a diagram confirming the delay in damage and the muscle fiber cross-sectional area (CSA) of the regenerated muscle through stem cell spheroid transplantation in an ischemic lower extremity disease animal model according to an embodiment of the present invention.
  • CSA muscle fiber cross-sectional area
  • Figure 10f is a diagram confirming the distribution of blood vessels in muscles regenerated through stem cell spheroid transplantation in an ischemic lower extremity disease animal model according to an embodiment of the present invention (BF: Bicep Femoris, CF: Caudofemoralis, SM: Semimembranosus).
  • Figure 11a is a diagram showing the appearance of a skin defect after treatment with a stem cell spheroid according to an embodiment of the present invention.
  • Figure 11b is a diagram showing the results of H&E staining of the tissue after treating the skin defect area with stem cell spheroids according to one embodiment of the present invention.
  • Figure 12 is a diagram showing the results of H&E staining and Oil red O staining of adipose tissue regenerated after transplanting a stem cell spheroid according to an embodiment of the present invention into the fat pad of an animal.
  • the present inventors manufactured standardized stem cell spheroids that can be manufactured in uniform sizes and confirmed the regenerative effect on various tissues such as salivary glands, trachea, vocal cords, muscles, skin, and fatty tissue. As a result, stem cell spheroids were created. It was confirmed that it has the effect of regenerating/reconstructing various tissues as described above through actions such as blood vessel formation, and that the tissue regeneration rate was faster than 2D cultured stem cells and the similarity to the original tissue was high. In addition, it was confirmed that when stem cell spheroids are mixed with a scaffold for tissue engineering, the expression of bioactive factors that promote tissue regeneration is improved, thereby improving tissue regeneration efficacy.
  • the present invention provides a composition for promoting tissue regeneration, comprising stem cell spheroids as an active ingredient.
  • stem cells are cells that form the basis of cells or tissues constituting an organism and are characterized by the ability to self-renew by dividing repeatedly and performing specific functions depending on the environment. It refers to a cell that has the ability to differentiate into other cells. It occurs in all tissues during fetal development, and even in adulthood, it is found in some tissues where cells are actively replaced, such as bone marrow and epithelial tissue.
  • stem cells include totipotent stem cells formed when a fertilized egg begins its first division, pluripotent stem cells in the inner membrane of the blastula created by continuous division of these cells, and They are classified as multipotent stem cells that exist in mature tissues and organs.
  • pluripotent stem cells are cells that can differentiate only into cells specific to the tissues and organs in which they are contained, and are responsible for the growth and development of each tissue and organ in the fetal, neonatal, and adult stages, as well as the homeostasis of adult tissues. It is involved in the function of maintaining and inducing regeneration when tissue is damaged. These tissue-specific pluripotent cells are collectively referred to as adult stem cells.
  • Mesenchymal stem cells classified as adult stem cells, are well known as repair cells of various connective tissues, and these cells can differentiate into various types of mesenchymal cells.
  • neural stem cells which are located deep in the brain and are difficult to obtain in sufficient quantity and have a risk of brain damage, and thus can be used for the development of treatments for neurological diseases and for regenerative medicine.
  • It is in the spotlight as a material, and can be collected from tissues such as bone marrow, umbilical cord blood, fat tissue, and umbilical cord.
  • tissues such as bone marrow, umbilical cord blood, fat tissue, and umbilical cord.
  • cells that make up various human tissues such as fat cells, osteocytes, cartilage cells, nerve cells, and cardiomyocytes. It has the ability to differentiate into
  • the stem cells include bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, embryonic stem cell-derived mesenchymal stem cells, tonsil-derived mesenchymal stem cells, and induced pluripotent stem cell-derived mesenchymal stem cells. It may be one or more selected from the group consisting of, but is not limited to this. According to one experimental example of the present invention, the tissue regeneration effect of stem cell spheroids prepared using embryonic stem cell-derived mesenchymal stem cells was confirmed, but the effect of stem cell spheroids is not limited to the experimental examples of the present invention. , the same effect can be achieved with other types of stem cells described above.
  • the tissue may be one or more selected from the group consisting of skin, fat, salivary glands, trachea, respiratory tract, vocal cords, and muscle.
  • the muscle may be a lower limb muscle, but is not limited thereto.
  • cell spheroid refers to cells cultured as three-dimensional spheroids, and since the original shape of cells in the body is three-dimensional, cell growth is higher in the spheroid form compared to cells cultured as a monolayer. It is excellent and can maintain the original characteristics of cells.
  • cell aggregate refers to a three-dimensional cell aggregate in which the expression of factors showing various pharmacological activities is increased as a hypoxic environment is induced by limiting oxygen delivery in the center of the cell spheroid.
  • the cell spheroid of the present invention contains factors that exhibit the above pharmacological activity, namely, vascular endothelial growth factor (VEGF), a tissue regeneration promoting factor known to promote tissue regeneration, and matrix metalloproteinase ( matrix metalloproteinases (MMPs), fibroblast growth factors (FGFs), epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth factors growth factors (PDGFs), placental growth factor (PlGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming growth factor beta (TGF-
  • cytokines necessary for cell growth and differentiation such as ⁇
  • angiopoietin angiopoietin
  • immune-related cytokines such as the interleukin family
  • VEGF promotes the formation of new blood vessels and promotes tissue regeneration. It is known to promote tissue regeneration by recruiting necessary cytokines and immune cells to damaged tissues. Therefore, the cell spheroid in which the expression of these factors of the present invention is promoted can be effectively used in the treatment of various diseases requiring tissue regeneration.
  • the stem cell spheroid includes measuring the diameter of the stem cell;
  • the diameter of the stem cells is preferably 1 to 50 ⁇ m, more preferably 3 to 30 ⁇ m, preferably 1 x 10 3 to 1 x 10 10 , more preferably 3 x 10 3 Dispensing from 3 to 3 x 10 6 stem cells into a culture vessel; And it can be prepared by a method comprising culturing the stem cells to obtain stem cell spheroids.
  • cells may be dispensed into the culture vessel as much as the required number (f) of initial single cells calculated by the formula below.
  • f refers to the required number of initial single cells
  • x refers to the diameter of the single cell
  • y refers to the diameter of the cell spheroid.
  • x 0 may be 8.2775 to 10.3231
  • y 0 may be 624.8576 to 726.3632
  • a 53.0017 to 89.4827
  • b 9.0232 to 10.2778
  • stem cell spheroids By producing stem cell spheroids using the above method and function, stem cell spheroids having a desired diameter can be uniformly produced.
  • the culturing step may include culturing the cells for preferably 2 to 7 days, more preferably 2 to 4 days, but is not limited thereto.
  • the composition may be in the form of a pharmaceutical composition, but is not limited thereto.
  • the composition may be used as a pharmaceutical composition for preventing or treating diseases requiring tissue regeneration, but is not limited thereto.
  • the present invention provides a pharmaceutical composition for preventing or treating diseases requiring tissue regeneration, comprising stem cell spheroids as an active ingredient.
  • the disease requiring tissue regeneration refers collectively to all diseases requiring tissue regeneration due to aging, damage, necrosis, etc., for example, bone, cartilage, skin, eardrum, lung, fat, cartilage, bone. , but is not limited to all diseases that require regeneration in tissues such as nerves, ligaments, tendons, vocal cords, heart, liver, uterus, salivary glands, trachea, airways, muscles, and esophagus.
  • the stem cell spheroids can also be used to regenerate damaged tissues in ischemic diseases. Alternatively, it can be used for tissue regeneration after tissue resection surgery, such as cancer resection surgery. However, the disease is not limited to this if it is a disease that can be treated by regenerating tissue using stem cells.
  • Ischemia refers to stenosis or constriction of blood vessels that supply blood to body organs, tissues or parts, or local necrosis of tissue due to problems in blood supply due to insufficient normal blood vessel formation. refers to a situation that has occurred.
  • the heart and brain are the body organs most sensitive to lack of blood flow, and when ischemia occurs in the tissue, a series of processes called ischemic cascade are triggered, causing permanent damage to the tissue.
  • the ischemic lower extremity disease may include ischemic lower extremity disease, cardiac angina, myocardial infarction, cerebral infarction, foot ulcer, etc., and the ischemic lower extremity disease may include lower extremity arterial occlusive disease, lower extremity arterial stenotic disease, lower extremity arteriosclerosis, etc.
  • the pharmaceutical composition according to the present invention may further include appropriate carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions.
  • the excipient may be, for example, one or more selected from the group consisting of diluents, binders, disintegrants, lubricants, adsorbents, humectants, film-coating materials, and controlled-release additives.
  • the pharmaceutical composition according to the present invention can be prepared as powder, granules, sustained-release granules, enteric-coated granules, solutions, eye drops, ellipsis, emulsions, suspensions, spirits, troches, perfumes, and limonadese according to conventional methods.
  • Carriers, excipients, and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, and calcium. These include phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Additives to tablets, powders, granules, capsules, pills, and troches according to the present invention include corn starch, potato starch, wheat starch, lactose, white sugar, glucose, fructose, di-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, and phosphoric acid.
  • Excipients such as cellulose (HPMC), HPMC 1928, HPMC 2208, HPMC 2906, HPMC 2910, propylene glycol, casein, calcium lactate, and Primogel; Gelatin, gum arabic, ethanol, agar powder, cellulose acetate phthalate, carboxymethyl cellulose, calcium carboxymethyl cellulose, glucose, purified water, sodium caseinate, glycerin, stearic acid, sodium carboxymethyl cellulose, sodium methyl cellulose, methyl cellulose, microcrystalline cellulose, dextrin.
  • binders can be used, Hydroxypropyl methyl cellulose, corn starch, agar powder, methyl cellulose, bentonite, hydroxypropyl starch, sodium carboxymethyl cellulose, sodium alginate, calcium carboxymethyl cellulose, calcium citrate, sodium lauryl sulfate, silicic anhydride, 1-hydroxy Propylcellulose, dextran, ion exchange resin, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate, polyvinylpyrrolidone, calcium phosphate, gelled starch, gum arabic, Disintegrants such as amylopectin, pectin, sodium polyphosphate, ethyl cellulose
  • soybean oil (Lubri wax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, Macrogol, synthetic aluminum silicate, silicic anhydride, higher fatty acids, higher alcohol, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, Lubricants such as starch, sodium chloride, sodium acetate, sodium oleate, dl-leucine, and light anhydrous silicic acid can be used.
  • Additives to the liquid according to the present invention include water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, sucrose monostearate, polyoxyethylene sorbitol fatty acid esters (twin esters), polyoxyethylene monoalkyl ethers, lanolin ethers, Lanolin esters, acetic acid, hydrochloric acid, aqueous ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethyl cellulose, sodium carboxymethyl cellulose, etc. can be used.
  • a solution of white sugar, other sugars, or sweeteners, etc. may be used in the syrup according to the present invention, and if necessary, flavoring agents, colorants, preservatives, stabilizers, suspending agents, emulsifiers, thickening agents, etc. may be used.
  • Purified water can be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. can be used as needed.
  • Suspensions according to the present invention include acacia, tragacantha, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose (HPMC), HPMC 1828, HPMC 2906, HPMC 2910, etc. Topics may be used, and surfactants, preservatives, stabilizers, colorants, and fragrances may be used as needed.
  • Injections according to the present invention include distilled water for injection, 0.9% sodium chloride injection, IV solution, dextrose injection, dextrose + sodium chloride injection, PEG, lactated IV solution, ethanol, propylene glycol, non-volatile oil - sesame oil.
  • solvents such as cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristic acid, and benzene benzoate;
  • Solubilizing agents such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, Tween, nicotinic acid amide, hexamine, and dimethylacetamide;
  • Weak acids and their salts acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptone, and buffering agents such as gums
  • Isotonic agents such as sodium chloride
  • Stabilizers such as sodium bisulfite (NaHSO 3 ) carbon dioxide gas, sodium metabisulfite (Na 2 S 2 O 5 ), sodium sulfite (Na 2 SO 3 ), nitrogen gas (N
  • Suppositories according to the present invention include cacao oil, lanolin, witepsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, a mixture of stearic acid and oleic acid, Subanal, cottonseed oil, peanut oil, palm oil, cacao butter + Cholesterol, lecithin, Lanet wax, glycerol monostearate, Tween or Span, Imhausen, monolene (propylene glycol monostearate), glycerin, Adeps solidus, Buytyrum Tego -G), Cebes Pharma 16, Hexalide Base 95, Cotomar, Hydrocote SP, S-70-XXA, S-70-XX75(S-70-XX95), Hydro Hydrokote 25, Hydrokote 711, Idropostal, Massa estrarium (A, AS, B, C, D, E, I, T), Massa-MF, Massaupol, Masupol-15, Neosupostal-
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include the extract with at least one excipient, such as starch, calcium carbonate, and sucrose. ) or prepared by mixing lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium styrate talc are also used.
  • Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups.
  • various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.
  • composition according to the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, activity of the drug, and the type of patient's disease. It can be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs used simultaneously, and other factors well known in the medical field.
  • the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art to which the present invention pertains.
  • the pharmaceutical composition of the present invention can be administered to an individual through various routes. All modes of administration are contemplated, including oral administration, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, paraspinal space (intrathecal) injection, sublingual administration, buccal administration, intrarectal injection, vaginal injection. It can be administered by internal insertion, ocular administration, ear administration, nasal administration, inhalation, spraying through the mouth or nose, dermal administration, transdermal administration, or direct implantation at the wound site.
  • the pharmaceutical composition of the present invention is determined depending on the type of drug as the active ingredient along with various related factors such as the disease to be treated, the route of administration, the patient's age, gender, weight, and severity of the disease.
  • the composition may further include a scaffold for tissue engineering, but is not limited thereto.
  • tissue engineering scaffolds they are being developed to replace the defective area in the event of tissue defects such as burns or cancer tissue removal.
  • the sole use of tissue engineering scaffolds not only significantly delays tissue regeneration but also causes rejection reactions such as inflammation. There are limits to tissue regeneration due to side effects.
  • tissue regeneration efficacy is improved when stem cell spheroids are mixed with a scaffold for tissue engineering.
  • the scaffold for tissue engineering can be implanted through surgery or using a syringe, and can be made of biocompatible or biodegradable polymers including poly(caprolactone) (PCL), or hydrogel. etc. may be included, but there is no limitation on the type.
  • PCL poly(caprolactone)
  • the composition may further include a scaffold for tissue engineering and two-dimensionally cultured stem cells, but is not limited thereto.
  • the scaffold may have two-dimensional cultured stem cells applied to the inside and stem cell spheroids applied to the outside, but is not limited thereto.
  • the present invention provides a composition or kit for promoting tissue regeneration, including a scaffold for tissue engineering on which two-dimensionally cultured stem cells are applied on the inside and stem cell spheroids on the outside.
  • kit refers to a tool that promotes tissue regeneration by including a scaffold for tissue engineering onto which the two-dimensionally cultured stem cells and stem cell spheroids are applied.
  • the kit of the present invention may include other commonly needed components, compositions, solutions, devices, etc.
  • the kit includes a container; instructions (manual); And it may include the support.
  • the container may serve to package the support, and may also serve to store and secure the support.
  • the material of the container may take the form of, for example, a bottle, a tub, a sachet, an envelope, a tube, an ampoule, etc., which may be partially or entirely made of plastic, glass, paper, or foil. , wax, etc.
  • the container may be equipped with a completely or partially removable closure that may initially be part of the container or may be attached to the container by mechanical, adhesive, or other means, and may also provide access to the contents by needle.
  • a stopper can be installed.
  • the kit may include an external package, and the external package may include instructions for use of the components.
  • the stem cell spheroid may have improved expression of bioactive factors related to promoting tissue regeneration, but is not limited thereto.
  • the bioactive factors include vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), fibroblast growth factors (FGFs), and epidermal growth factors.
  • VEGF vascular endothelial growth factor
  • MMPs matrix metalloproteinases
  • FGFs fibroblast growth factors
  • epidermal growth factor EGF
  • Epidermal growth factor EGF
  • HGF hepatocyte growth factor
  • PDGFs platelet-derived growth factors
  • PlGF placental growth factor
  • granulocyte macrophage colony It may be one or more selected from the group consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming growth factor beta (TGF- ⁇ ), and angiopoietin, It is not limited to this.
  • GM-CSF granulocyte-macrophage colony-stimulating factor
  • TGF- ⁇ transforming growth factor beta
  • angiopoietin It
  • the stem cells can promote new blood vessel formation, but are not limited thereto.
  • new blood vessel formation is a physiological process in which new blood vessels are formed from existing blood vessels, and is formed in the early stages of blood vessel formation.
  • Neovascularization continues the growth of the vasculature primarily by sprouting and splitting processes, but processes such as adhesive neovascularization, vessel elongation, and vessel fusion also play a role.
  • Angiogenesis is a normal and important process in growth and development, wound healing, and granulation tissue formation.
  • the stem cell spheroid can effectively promote tissue regeneration by promoting the secretion of various pharmacologically active factors such as angiogenic factors and cell growth factors by inducing a low oxygen environment inside, but is not limited to this.
  • the cell spheroid has a diameter of 100 to 500 ⁇ m, 100 to 450 ⁇ m, 100 to 400 ⁇ m, 100 to 350 ⁇ m, 100 to 300 ⁇ m, 100 to 250 ⁇ m, 100 to 200 ⁇ m, 150 to 500 ⁇ m.
  • the present invention provides a cell therapeutic agent for promoting tissue regeneration, comprising stem cell spheroids as an active ingredient.
  • cell therapy refers to a stem cell spheroid produced using stem cells produced through isolation, culture, and special manipulation from mammals, and is used for the purposes of treatment, diagnosis, and prevention.
  • a pharmaceutical US FDA regulations
  • the cell therapeutic agent of the present invention may contain one or more active ingredients that exhibit the same or similar functions in addition to the stem cell spheroid.
  • it can be prepared by additionally including one or more pharmaceutically acceptable carriers.
  • Pharmaceutically acceptable carriers include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, colorants, flavorings, etc.
  • the cell therapy formulation of the present invention can be prepared in various ways by mixing it with a pharmaceutically acceptable carrier as described above.
  • a pharmaceutically acceptable carrier as described above.
  • it can be manufactured in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, it can be manufactured in the form of unit dosage ampoules or multiple dosage forms. there is.
  • it can be formulated as a solution, suspension, tablet, capsule, sustained-release preparation, etc.
  • the route of administration of the cell therapy according to the present invention is not limited to these, but is oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, Includes sublingual or rectal areas. Oral or parenteral administration is preferred.
  • parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • the stem cell therapeutic agent of the present invention depends on several factors, including the activity of the cell therapeutic agent used, age, body weight, general health, gender, dosage, administration time, administration route, excretion rate, drug formulation, and the severity of the specific disease to be prevented or treated. It may vary in various ways and may be appropriately selected by a person skilled in the art.
  • the number of stem cell spheroids is 10 to 18,000, 100 to 18,000, 500 to 18,000, 1000 to 18,000, 5,000 to 18,000, 10,000 to 18,000, and 15,000 to 18,000. , 15,500 to 18,000, 16,000 to 18,000, 15,000 to 17,000, 15,500 to 17,000, 16,000 to 17,000, 15,000 to 16,000, 15,500 to 16, 000 doses, or 16,000 doses. You can.
  • the above administration may be administered once a day or in divided doses. Additionally, when formulated as a liquid unit preparation such as solution, suspension, or emulsion, it can also be administered to patients at the above cell concentration.
  • the present invention provides a method for promoting tissue regeneration, comprising administering a composition containing stem cell spheroids as an active ingredient to an individual in need thereof.
  • the present invention provides a use for promoting tissue regeneration of a composition containing stem cell spheroids as an active ingredient.
  • the present invention provides the use of a composition containing stem cell spheroids as an active ingredient for the production of an agent for promoting tissue regeneration.
  • “individual” refers to a subject in need of treatment for a disease, and more specifically, human or non-human primates, mice, rats, dogs, cats, horses, cows, etc. refers to mammals of
  • “administration” means providing a given composition of the present invention to an individual by any appropriate method.
  • prevention refers to any action that suppresses or delays the onset of the desired disease
  • treatment refers to the improvement or improvement of the desired disease and its associated metabolic abnormalities by administration of the pharmaceutical composition according to the present invention. It refers to all actions that are beneficially changed.
  • BM-MSC bone marrow-derived mesenchymal stem cells
  • adipose-derived mesenchymal stem cells adipose cultured as a monolayer.
  • AD-MSC -derived mesenchymal stem cells
  • iPS-MSC induced pluripotent-derived mesenchymal stem cells
  • the isolated single cells were prepared at various concentrations, distributed at 50 ⁇ L each along with culture medium into an agar mold with 35 grooves of a certain size, and cultured at 37°C and 5% CO 2 conditions.
  • the initial number of stem cells used in culture was 1 x 10 4 to 30 x 10 4 cells/well for AD-MSC and 1 x 10 4 to 69 x 10 4 cells/well for BM-MSC and iPS-MSC.
  • the diameter of stem cell spheroids according to the number of single cells was measured on days 1, 3, and 5. The results are shown in Figure 1.
  • Example 2 Measurement of the required number of single cells according to the diameter of stem cell spheroids
  • the diameter of the stem cell spheroid formed after 3 days was measured, and the diameters were 150 ⁇ 10 ⁇ m, 200 ⁇ 10 ⁇ m, and 250 ⁇ 10 ⁇ m.
  • the relationship between the initial number of single cells and cell diameter of each stem cell spheroid was analyzed through logistic regression (Polynominal, Linear regression, SigmaPlot12.0), and a regression line was derived.
  • the diameter of single cells was found to be 10.4 ⁇ 3.8 ⁇ m and 15.2 ⁇ 8.5 ⁇ m for BM-MSCs, 14.0 ⁇ 2.4 ⁇ m for iPS-MSCs, and 21.9 ⁇ 7.1 ⁇ m for AD-MSCs. The results are shown in Figure 2.
  • the function for calculating the initial required number of single cells required to produce a cell spheroid having the target diameter is as follows.
  • f is the required number of single cells
  • x is the diameter of the single cell
  • y is the diameter of the cell spheroid
  • x 0 shows significant results when 8.2775 to 10.3231
  • y 0 is 624.5876 to 726.3632
  • a 53.0017 to 89.4827
  • b 9.0232 to 10.2778
  • c 162.0563 to 191.5685, especially
  • the initial required number of single cells when producing a cell spheroid of the desired diameter can be quantified. Additionally, regardless of the type of stem cell, the diameter of a single cell acts as an important factor in determining the spheroid diameter.
  • Example 3 Confirmation of method for measuring required number of single cells according to stem cell spheroid diameter
  • LDL Lectin-like oxidized low-density lipoprotein
  • Example 2 In order to determine the cell survival rate according to the diameter of the stem cell spheroid, the function established in Example 2 to determine the initial required number of single cells required to produce a stem cell spheroid of the target diameter was used to extract the embryo. After preparing stem cell spheroids with a diameter of 100 to 300 ⁇ m using cell-derived mesenchymal stem cells, they were further cultured for 7 days and cell viability was confirmed using Alamar Blue assay. The results are shown in Figure 5b.
  • cell survival rate is reduced in cell spheroids with a diameter of 250 ⁇ m or more, which induces a hypoxic environment inside the spheroid, which results in increased cell death.
  • each single cell dispersion 50 ⁇ L was dispensed into an agar mold with 35 grooves of a certain size, and then 450 ⁇ L of culture medium was added. and cultured at 37°C and 5% CO 2 conditions. The initial number of stem cells used in culture was 1.71 were dispensed respectively . To achieve a diameter of 200 ⁇ m, 4.28 , BM-MSC were dispensed at 12.86 x 10 3 cells, respectively. Then, the culture medium was replaced with new culture medium every day, and the culture medium cultured for 24 hours was collected and the secretion amount of bioactive factors was measured using ELISA.
  • bioactive factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinase-1 (MMP-1). was confirmed. 35 stem cell spheroids were maintained in each mold, and the amount of medium was maintained at 500 ⁇ L. The cumulative secretion amount of pharmacologically active factors is shown in Figure 5c.
  • VEGF vascular endothelial growth factor
  • bFGF basic fibroblast growth factor
  • MMP-1 matrix metalloproteinase-1
  • VEGF known to induce neovascularization
  • stem cell spheroids with a diameter of 250 ⁇ m compared to stem cell spheroids with a diameter of 150 ⁇ m. It was confirmed that the expression level increased by up to 8 times or more compared to cell spheroids.
  • bFGF which is known to promote cell growth, was also confirmed to have the highest expression level in stem cell spheroids with a diameter of 250 ⁇ m.
  • the expression level is low in BM-MSCs, but the expression level is highest in stem cell spheroids with a diameter of 250 ⁇ m.
  • AD-MSCs it was confirmed that the highest expression level was observed in stem cell spheroids with a diameter of 250 ⁇ m.
  • the expression level of bioactive factors increased in stem cell spheroids with a diameter of 200 ⁇ m or more induced in a hypoxic environment inside the cell, and through this, stem cell spheroids with a diameter of 200 ⁇ m to 400 ⁇ m were confirmed. It was predicted that the tissue regeneration effect would be high.
  • stem cell spheroids were prepared in the same manner as in Examples 1 and 2 using embryonic stem cell-derived mesenchymal stem cells, and the culture medium cultured for 3 days was recovered and used as a Proteome Profiler Human Angiogenesis Array Kit (R&D System).
  • Various bioactive factors involved in the neovascularization process were identified using . As a result, as shown in Figure 5d, it was confirmed that the expression level of angiogenesis-inducing factors in stem cell spheroids increased compared to single cells.
  • VEGF vascular endothelial growth factor
  • GFP-HUVECs green fluorescent protein-expressing human umbilical vein endothelial cells
  • a Matrigel ® matrix excluding growth factors was coated on a 24-well plate, and 2.6 x 10 3 cells/cm 2 of HUVECs were dispensed. . Then, 20 stem cell spheroids were dispensed onto the top of the plate using a transwell system and cultured for 6 to 24 hours. At this time, the stem cell spheroid was prepared in the same manner as in Examples 1 and 2 using embryonic stem cell-derived mesenchymal stem cells, and was manufactured very uniformly. Stem cell spheroids were 300 ⁇ m in diameter spheroids cultured on the 3rd day. After 6 and 24 hours of culture, master junctions and master segments were analyzed and quantified using ImageJ angiogenesis analysis.
  • anti-VEGF which is an antagonist of VEGF expressed in stem cell spheroids
  • VEGF affecting GFP-HUVEC was limited to that expressed by stem cell spheroids.
  • the amount of anti-VEGF was half (0.53 pM) and the same amount (1.07 pM) compared to the amount expressed by 20 stem cell spheroids with a diameter of 300 ⁇ m.
  • mice (Balb.c/nude, 12 months, male) were used, and to induce solid tumors in the oral cavity, 5 x 10 5 SNU-1041 cells were dispersed in 20 ⁇ l of PBS and anesthetized. The right side of the tongue was injected using a 27 G insulin syringe. As an anesthetic, zoletile/rampun was used diluted 1:3.
  • the anesthetized mouse was placed in a supine position, and then the area including the salivary glands and tongue was treated with radiation at an intensity of 15 Gy once using the 21EX-S equipment. 48 hours after irradiation, the anesthetized mouse was placed in a supine position, a 1 cm incision was made in the skin under the chin to expose the salivary gland tissue, and 81 embryonic stem cell-derived mesenchymal stem cell spheroids were injected using a 23 G puncture needle. did. At this time, the stem cell spheroids were dispersed in 20 ⁇ l of saline solution.
  • the tumor was initially suppressed by irradiation, but the mucin secretion function decreased as the salivary glands were damaged due to the effects of irradiation, but the mucin secretion function was reduced by injecting stem cell spheroids.
  • the mucin secretion function was noticeably improved by stem cell spheroid injection even though the salivary glands were exposed to radiation.
  • PCL poly(caprolactone)
  • a tracheal defect model was prepared by creating a 5 mm x 9 mm defect in the trachea of a male New Zealand White rabbit. Then, the defect was sutured using a poly(caprolactone) (PCL) nanofiber membrane (9 mm x 11.5 mm) as a tracheal support.
  • PCL poly(caprolactone)
  • 320 embryonic stem cell-derived mesenchymal stem cell spheroids were applied to the outside of the scaffold, and 2D cultured stem cells were 1.6 x 10 6 cells/.
  • the scaffold was applied inside the support to observe regeneration of the airway mucosa and formation of new blood vessels.
  • gauze coated with agar gel was used to create an environment so that the used cells could fully attach to the scaffold. As a result, as shown in Figure 8a, it was confirmed that all cells were attached to the organ support regardless of the shape of the stem cells, and it was confirmed that viability was also excellent.
  • Organ tissues were recovered and histopathological analysis was performed. As a result of immunostaining of the regenerated organ tissue, as shown in Figure 8d, basal cells were confirmed in all experimental groups, confirming the possibility of regeneration into the airway mucosa. Compared to the case of transplantation with scaffold alone, it was confirmed that a regenerative effect was observed when 2D cultured stem cells and stem cell steroids were applied respectively. In particular, 2D cultured stem cells and stem cell spheroids were confirmed to have a regenerative effect. When applied to the inside and outside of the support, it was confirmed that even the cells of the airway mucosa layer were regenerated. In addition, when both 2D cultured stem cells and stem cell spheroids were applied, more proliferating cells were identified compared to other experimental groups. Through this, it was confirmed that a synergistic effect appears when both types of cells are used.
  • goblet cells secreting mucin were confirmed through alcian blue staining.
  • two-dimensionally cultured stem cells were placed inside the scaffold. Distinct goblet cells were confirmed when applied and when 2D cultured stem cells and stem cell spheroids were applied to the inside and outside of the scaffold, respectively.
  • a similar trend was confirmed in beta-tubulin immunostaining to confirm cilia formation.
  • stem cell spheroids with enhanced expression of angiogenesis-inducing factors were applied to the outside of the scaffold, blood vessels formed in the tissue outside the scaffold were also observed, and as a result, as shown in the right drawing of Figure 8f, the stem cell spheroids were applied to the outside of the scaffold.
  • CD31-positive cells were identified the most, and ⁇ -SMA-positive cells, which confirmed developed blood vessels, were also observed and confirmed to have a distinct ductal shape.
  • ischemic lower extremity disease animal model was constructed as reported in a previous study (Nat Protoc. 2009;4(12):1737-46.). Briefly, the femoral artery and vein were bluntly dissected and separated after a surgical skin incision (5 mm) starting from the inguinal skin fold immediately adjacent to the vessel outline visible through the mouse skin. Then, a surgical thread was inserted under the femoral artery, the femoral artery distal to the deep branch origin was ligated with a triple surgical knot, and the skin was sutured.
  • the damaged blood vessel area is covered with growth factor-excluding Matrigel containing optimized embryonic stem cell-derived mesenchymal stem cell spheroids, and then the angiogenic factors expressed by the stem cell spheroids are covered. It was verified whether they showed efficacy in delaying vascular damage. As a result, as shown in Figures 10b and 10c, there was no significant difference in blood flow measurement for each experimental group on the 5th day after transplantation, but it was confirmed that the feet of animals in all experimental groups except the experimental group transplanted with stem cell spheroids were damaged.
  • stem cell spheroids and 2D cultured stem cells had been transplanted.
  • the shape of the foot was maintained and blood flow was restored, whereas when two-dimensional cultured stem cells were transplanted, the initially damaged shape of the foot was not restored. From this, it was confirmed that stem cell spheroid transplantation not only delays the progression of ischemic lower extremity disease, but also regenerates damaged blood vessels.
  • mice Male, 13 months were used to verify the efficacy of stem cell spheroids in regenerating skin defects. As aged animals were used, their own tissue regeneration function deteriorated due to aging, resulting in the expression of stem cell spheroids. It was expected that tissue regeneration speed would be improved by bioactive factors.
  • T-seal fibrin sealant, Baxter Healthcare Corp., Deerfield, IL
  • Tisseel was used to repair the defect area and fix the stem cells and stem cell spheroids applied to the defect area. 7 days after treatment, as a result of visual inspection, contraction of the wound area was confirmed when only T-Seal was treated, as shown in Figure 11a.
  • the fat pad of a Balb/c-nude mouse male, 13 months was incised and Matrigel, Matrigel encapsulated with two-dimensional cultured stem cells, and Matrigel encapsulated with stem cell spheroids were implanted, respectively. And the fat reconstruction efficacy of stem cell spheroids was verified.
  • Matrigel with reduced growth factors was used to enable fat regeneration to be induced by bioactive factors expressed by stem cell spheroids.
  • the fat reconstruction/regeneration speed of stem cell spheroids was confirmed by using male experimental animals with slow fat reconstruction and regeneration speed.
  • the stem cell spheroid according to the present invention has an excellent effect on the regeneration of various tissues such as salivary glands, trachea, vocal cords, muscles, skin, and fatty tissue through actions such as formation of new blood vessels, and is used as a cell therapy for various tissue diseases, etc. It is expected to be useful and has potential for industrial use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition permettant de favoriser la régénération tissulaire, la composition comprenant des sphéroïdes de cellules souches. Les sphéroïdes de cellules souches selon la présente invention peuvent être produits à une taille uniforme et sont normalisés, la vitesse de régénération tissulaire est plus rapide que celle de cellules souches cultivées dans deux dimensions, et le tissu régénéré a un degré élevé de similarité avec le tissu d'origine. Les sphéroïdes de cellules souches selon la présente invention présentent un excellent effet sur la régénération de différents tissus tels que les glandes salivaires, les organes, les cordes vocales, les muscles, la peau et le tissu adipeux par l'intermédiaire d'une activité telle que l'angiogenèse, et devraient donc être utiles en tant que thérapie cellulaire, pour différentes maladies tissulaires, et similaires.
PCT/KR2023/018404 2022-11-15 2023-11-15 Composition permettant de favoriser la régénération tissulaire comprenant des sphéroïdes de cellules souches WO2024106959A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20220153034 2022-11-15
KR10-2022-0153034 2022-11-15
KR1020230158492A KR20240072071A (ko) 2022-11-15 2023-11-15 줄기세포 스페로이드를 포함하는 조직 재생 촉진용 조성물
KR10-2023-0158492 2023-11-15

Publications (1)

Publication Number Publication Date
WO2024106959A1 true WO2024106959A1 (fr) 2024-05-23

Family

ID=91084963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/018404 WO2024106959A1 (fr) 2022-11-15 2023-11-15 Composition permettant de favoriser la régénération tissulaire comprenant des sphéroïdes de cellules souches

Country Status (1)

Country Link
WO (1) WO2024106959A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160000030A (ko) * 2014-06-23 2016-01-04 단국대학교 천안캠퍼스 산학협력단 피부 또는 혈관조직 손상 치료 보조용 약학 조성물
KR101922346B1 (ko) * 2017-09-14 2018-11-26 서울대학교병원 궤양 치료용 줄기세포 스페로이드-시트 복합체 및 이의 제조방법
KR20210021165A (ko) * 2019-08-14 2021-02-25 아주대학교산학협력단 지방줄기세포 유래 스페로이드를 포함하는 조건 배지를 유효성분으로 포함하는 상처 치유용 약학 조성물
KR20210059809A (ko) * 2019-11-14 2021-05-26 인천대학교 산학협력단 줄기세포 스페로이드로부터 유래된 조직 비드를 포함하는 이식용 조성물
KR20210067988A (ko) * 2019-08-12 2021-06-08 의료법인 성광의료재단 Ｍａｔｒｉｌｉｎ-3 전처리 줄기세포 스페로이드 생산 방법, 및 그에 의해 도출된 연골질환 예방 또는 치료용 조성물
KR20220062167A (ko) * 2020-11-06 2022-05-16 가톨릭대학교 산학협력단 결합조직 성장인자를 유효성분으로 포함하는 줄기세포 스페로이드의 골분화 촉진용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160000030A (ko) * 2014-06-23 2016-01-04 단국대학교 천안캠퍼스 산학협력단 피부 또는 혈관조직 손상 치료 보조용 약학 조성물
KR101922346B1 (ko) * 2017-09-14 2018-11-26 서울대학교병원 궤양 치료용 줄기세포 스페로이드-시트 복합체 및 이의 제조방법
KR20210067988A (ko) * 2019-08-12 2021-06-08 의료법인 성광의료재단 Ｍａｔｒｉｌｉｎ-3 전처리 줄기세포 스페로이드 생산 방법, 및 그에 의해 도출된 연골질환 예방 또는 치료용 조성물
KR20210021165A (ko) * 2019-08-14 2021-02-25 아주대학교산학협력단 지방줄기세포 유래 스페로이드를 포함하는 조건 배지를 유효성분으로 포함하는 상처 치유용 약학 조성물
KR20210059809A (ko) * 2019-11-14 2021-05-26 인천대학교 산학협력단 줄기세포 스페로이드로부터 유래된 조직 비드를 포함하는 이식용 조성물
KR20220062167A (ko) * 2020-11-06 2022-05-16 가톨릭대학교 산학협력단 결합조직 성장인자를 유효성분으로 포함하는 줄기세포 스페로이드의 골분화 촉진용 조성물

Similar Documents

Publication Publication Date Title
WO2018026203A1 (fr) Composition pour prévenir ou traiter la fibrose pulmonaire comprenant comme principe actif un exosome issu de cellules souches dérivées du tissu adipeux
WO2011056017A2 (fr) Procédé de propagation en masse pour des cellules souches de follicule pileux
WO2017175909A1 (fr) Composition pharmaceutique pour la cicatrisation des plaies contenant de la substance p
WO2021206459A1 (fr) Exosomes dérivés de cellules souches contenant des régulateurs de la douleur, et leurs utilisations
KR101777414B1 (ko) 줄기세포 및/또는 전구세포의 활성화제
WO2014185620A1 (fr) Composition de cellules souches pour administration veineuse
WO2024106959A1 (fr) Composition permettant de favoriser la régénération tissulaire comprenant des sphéroïdes de cellules souches
WO2019151744A1 (fr) Nanovésicules dérivées de cellules souches adultes et leur utilisation pour une thérapie ciblée
WO2019144967A1 (fr) Méthode pour détruire l'homéostasie cellulaire mécanique et favoriser la régénération et la réparation des tissus et des organes, et son utilisation
WO2021071289A2 (fr) Composition permettant d'augmenter le caractère souche et son utilisation
WO2022010181A1 (fr) Composition pour prévenir ou traiter des maladies du cerveau et du système nerveux
WO2023191225A1 (fr) Composition de milieu pour la préparation d'organoïde intestinal
KR20240072071A (ko) 줄기세포 스페로이드를 포함하는 조직 재생 촉진용 조성물
WO2010077093A9 (fr) Composition favorisant la croissance des cheveux ou empêchant la perte de cheveux comprenant de l'érythropoïétine
US20240218016A1 (en) Peptides and their use in the treatment of inflammation
KR102210807B1 (ko) 편도유래 줄기세포를 포함하는 구강 점막염 치료용 조성물, 및 구강 점막염 동물모델 제조방법
KR102551880B1 (ko) 부신피질자극호르몬분비호르몬을 유효성분으로 포함하는 신경세포구 형성 촉진용 조성물
KR102525093B1 (ko) 사람 신경능 유래 코 하비갑개 줄기세포를 유효성분으로 포함하는 망막변성질환 예방 또는 치료용 약학적 조성물
WO2023043191A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie hépatique comprenant un milieu de culture de cellules souches surexprimant la protéine iap
WO2022220501A1 (fr) Composition contenant une cellule souche mésenchymateuse et une cellule progénitrice endothéliale vasculaire en tant que principe actif pour la prévention ou le traitement d'une maladie vasculaire occlusive ou d'une complication associée
WO2021187895A1 (fr) Composition pour la prévention ou le traitement de maladies ischémiques comprenant des cellules souches cardiaques
WO2018088821A1 (fr) Composition favorisant l'activité des cellules souches, comprenant un inhibiteur d'histone désacétylase et un facteur d'amorçage en tant que principes actifs
WO2023043152A1 (fr) Exosomes ciblant des hépatocytes et leur utilisation pour la prévention ou le traitement d'une maladie hépatique
WO2014042292A1 (fr) Composition comprenant un activateur de la protéine kinase c destiné à favoriser l'adhérence de cellules souches et méthode destinée à favoriser l'adhérence de cellules souches
WO2022055238A1 (fr) Composition destinée au traitement de maladies osseuses comprenant un exosome dérivé d'une cellule souche mésenchymateuse adipeuse épidurale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23892024

Country of ref document: EP

Kind code of ref document: A1